As of Tuesday, February 10, 2026, According to CoinMarketCap data, Jupiter (JUP) is currently trading at $0.1553, down 3% over the past 24 hours. Despite the shortAs of Tuesday, February 10, 2026, According to CoinMarketCap data, Jupiter (JUP) is currently trading at $0.1553, down 3% over the past 24 hours. Despite the short

Jupiter’s Critical $0.15 Support May Trigger $1.50 Rally

2026/02/10 14:00
2 min read

As of Tuesday, February 10, 2026, According to CoinMarketCap data, Jupiter (JUP) is currently trading at $0.1553, down 3% over the past 24 hours.

Despite the short-term dip, daily trading volume rose 1.55% to $27.35 million, suggesting renewed market engagement as the token tests a critical technical support zone. Over the past seven days, JUP has declined 19.72%, reflecting broader market caution and continued bearish pressure.

Source: CoinMarketCap

JUP Price Near Critical Support Zone

In X post, Crypto analyst Jonathan Carter of Crypto Insights commented, “The convergence of JUP’s descending channel lower boundary with horizontal support suggests a potential rebound. 

If the support holds, JUP could rally toward targets between $0.23 and $1.50, although medium-term momentum remains bearish below the 50-day moving average.” Carter emphasized that failure to hold this support could extend downward pressure along the channel.

Technical charts show that Jupiter has maintained lower lows and lower highs while respecting the descending channel’s structure. Volume analysis indicates a modest uptick near the support zone, suggesting growing buying interest. Traders eyeing long-term swing opportunities may consider the $0.15 area as a potential entry point.

Market projections outline multiple resistance targets at $0.23, $0.33, $0.45, $0.65, $0.97, and $1.50, highlighting a high risk-to-reward scenario for long positions. Experts caution that if the support fails, the price may continue along the channel’s downward trend, invalidating bullish scenarios.

Source: X

Polymarket Expands to Solana via Jupiter Integration

In a parallel development, Jupiter recently announced the integration of Polymarket’s decentralized prediction markets directly into its platform, expanding Solana’s role in event-based trading. The collaboration enables users to trade prediction contracts across politics, sports, macroeconomics, and cultural events without leaving the Jupiter interface.

Polymarket recorded $7.66 billion in trading volume in January 2026, up from $5.31 billion in December, while rival platform Kalshi reported $9.16 billion, reflecting accelerating adoption of regulated and crypto-native prediction markets.

Industry analysts say Jupiter’s integration positions Solana as a leading blockchain hub for prediction markets, merging decentralized finance infrastructure with mainstream trading accessibility.

Also Read | Jupiter (JUP) Eyes $0.42 Breakout as Triangle Apex Approaches

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0005093
$0.0005093$0.0005093
+8.75%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26